TSHA (Taysha Gene Therapies, Inc.) Stock Financials & Earnings

TSHATaysha Gene Therapies, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$6M

Net Income (TTM)-$100M

EPS (TTM)-$0.35

Free Cash Flow (TTM)-$85M

Gross Margin95.5%

Op. Margin-1618.5%

Net Margin-1583.7%

FCF Margin-1349.6%

P/S Ratio (TTM)175.4x

P/E Ratio (TTM)—

YoY Rev Growth-36.4%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$3M	$823K	-$19M
Q1 23	$5M	$4M	-$17M
Q2 23	$2M	$2M	-$23M
Q3 23	$5M	$4M	-$16M
Q4 23	$4M	$4M	-$16M
Q1 24	$3M	$3M	-$24M
Q2 24	$1M	$1M	-$21M
Q3 24	$2M	$2M	-$26M
Q4 24	$2M	$2M	-$20M
Q1 25	$2M	$2M	-$21M
Q2 25	$2M	$2M	-$27M
Q3 25	$0	-$286K	-$34M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$14M	—	$6M
Q1 23	$13M	—	$8M
Q2 23	$20M	—	$5M
Q3 23	$12M	—	$8M
Q4 23	$13M	$7M	—
Q1 24	$21M	$7M	—
Q2 24	$15M	$7M	—
Q3 24	$15M	$8M	—
Q4 24	$15M	$7M	—
Q1 25	$16M	$8M	—
Q2 25	$20M	$9M	—
Q3 25	$25M	$8M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$88M	$0	$88M
Q1 23	$63M	$0	$63M
Q2 23	$45M	$0	$45M
Q3 23	$164M	$0	$164M
Q4 23	$144M	$0	$144M
Q1 24	$124M	$0	$124M
Q2 24	$173M	$0	$173M
Q3 24	$158M	$0	$158M
Q4 24	$139M	$0	$139M
Q1 25	$117M	$0	$117M
Q2 25	$313M	$0	$313M
Q3 25	$297M	$0	$297M

Shares Outstanding

Revenue Per Employee

Revenue / Employee